Drugs / Creatinine
Creatinine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05105009 | Mar 2020 → Oct 2023 | chronic renal failure syndrome | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Creatinine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105009 ↗ |
| Known as | 1-methylglycocyamidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL65567 ↗ |
| Known as | 1-methylhydantoin-2-imide | ChEMBL registry synonym — accepted as the source's own label CHEMBL65567 ↗ |
| Known as | Kreatininum | ChEMBL registry synonym — accepted as the source's own label CHEMBL65567 ↗ |
| Known as | NSC-13123 | ChEMBL registry synonym — accepted as the source's own label CHEMBL65567 ↗ |
| Action | Inhibit | “one OCT (OCT2 blocked by creatinine)” NCT05105009 ↗ |
| Modality | Small molecule | — CHEMBL65567 ↗ |
| Route | Oral | “5g of creatinine (Sigma) in 250 ml of water was taken orally” NCT05105009 ↗ |